- Advertisement -
Vaccinate and track, this is the mission that the Ivorian health authorities carried out before the discovery of a case of Ebola in Abidjan. This is a cause for concern, but the Ministry of Health very quickly set up an action plan to vaccinate healthcare staff who take care of the patient as quickly as possible.
as reported from Abidjan, Jean-Luc Aplogan
The first doses of the Ebola vaccine were administered Monday evening, August 16, in small cabins in the emergency room at Cocody University Hospital. The current operation is then aimed at a small group of health workers the sick young woman went through this service before landing in Treichville where she is being cared for. Teams in overalls came earlier to disinfect this service.
The Ivorian authorities have received 5,000 doses of vaccines against Ebola on Sunday 15 August from Conakry. These doses make it possible to vaccinate the target group after having had direct or indirect contact with the young patient.
The health care system is currently ready to respond to the various warnings. And if there are cases, we can take care of them.
Professor Paul Serge Eholié on dealing with the Ebola crisis
Tracing still ongoing When it comes to tracing these contact matters, investigations are ongoing. The itinerary for the young 18-year-old patient is fully tracked. The manifesto for the bus she was traveling on helps a lot. The bus, the driver, his apprentice, the host family and some travel companions were found. They are monitored by a medical team with regular temperature measurements. These people will be vaccinated.
There were 68 passengers on board this bus from Guinea. Of this number, 33 arrived in Abidjan with the patient, the rest had gone down on the way to other destinations.
Ervebo, Ebola vaccine
Ervebo was developed by researchers in Canada and manufactured by the American laboratory Merck. The vaccine targets the deadliest Ebola virus from Zaire. It was this tribe that hit Guinea in 2013 and then spread to Liberia and Sierra Leone, killing more than 11,000 in total. At that time, the scale of the epidemic, the largest to date, aroused the search for an effective vaccine. In 2019, the WHO will certify this first vaccine against the Ebola virus. It is also recognized by the United States and the European Union. Scientific data report an effect of over 97% with a single injection for people over 18 years of age.
This vaccine actually consists of a live virus that is virtually harmless to humans, the vesicular stomatitis virus, which is further weakened and modified to simply contain an envelope protein from the Ebola virus, which is sufficient for our purposes. Immune system to recognize and stop the infection. Ervebo does not contain the entire Ebola virus and therefore cannot transmit the disease. The downside is that this vaccine must be stored between -60 and -80 ° C, but this did not prevent its use in the Democratic Republic of Congo, especially during the tenth outbreak in the country between 2018 and 2020 or even in February 2021 in Guinea.
.
